Baird lowered the firm’s price target on Global Medical REIT (GMRE) to $9 from $10 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which were ahead due to NOI and guidance was unchanged.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMRE:
- Strategic Positioning and Strong Financial Performance Drive Buy Rating for Global Medical REIT
- Cautious Hold Rating on Global Medical REIT Amid Financial Strain and Strategic Uncertainty
- Global Medical REIT reports Q1 AFFO 22c, consensus 22c
- Global Medical REIT backs FY25 AFFO view 89c-93c, consensus 91c
- GMRE Earnings Report this Week: Is It a Buy, Ahead of Earnings?